ReviewFrontiers in immunology2026
Mitochondrial transfer: a new perspective on tumor-microenvironment crosstalk driving metastasis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor metastasis is the leading cause of cancer-related deaths. It depends not only on the intrinsic properties of cancer cells but also on their active shaping of the tumor microenvironment. Recent studies have identified mitochondrial transfer(MT) as a key mechanism underlying this tumor-microenvironment crosstalk. Beyond serving as a simple metabolic rescue pathway, MT functions as an intercellular reprogramming process that promotes metastatic progression. In this Review, we propose that MT acts as a tripartite educator during metastasis by driving three coordinated programs: metabolic licensing, immune rewiring, and stromal remodeling. Metabolic licensing enhances the survival and invasive capacity of cancer cells. Immune rewiring helps tumor cells evade immune surveillance. Stromal remodeling reprograms the tumor microenvironment into a permissive niche that supports tumor establishment. We summarize current evidence supporting each of these three programs and discuss emerging therapeutic strategies aimed at either blocking pathological MT or exploiting it for antitumor intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.